# Jedrzej Litwiniuk

> Jedrzej (Jed) Litwiniuk is the co-founder and CEO of Auxilius Pharma, a Boston- and New York-based pharmaceutical company built on the idea that the next breakthrough heart drug might already exist - it just needs to be reformulated. A corporate-finance and investment hand who crossed from PZU and LUX MED deal tables into the lab, he is steering AUX-001, a once-daily reformulation of nicorandil aimed at becoming the first new oral therapy for chronic stable angina in the US since 2006. In December 2025 the company closed a $4 million Series A to push the candidate through pharmaceutical optimization and a Phase Ib trial.

- **Role:** Co-Founder & CEO at Auxilius Pharma
- **Organizations:** Auxilius Pharma, Picket Pharmaceuticals, PZU, LUX MED, JPMorgan Chase
- **Nationality:** Polish
- **Education:** Executive Master of Health Administration (MHA), Columbia University Mailman School of Public Health
- **Known for:** Co-founded and leads Auxilius Pharma, focused on value-added cardiovascular medicines, Advanced AUX-001 toward becoming the first new oral chronic stable angina therapy in the US since 2006, Secured FDA acceptance of a 505(b)(2) regulatory pathway, bypassing Phase II

## Career timeline

- **early career** — Intern at JPMorgan Chase
- **earlier** — Director, Investment at PZU, a major Polish insurer
- **earlier** — Manager, Mergers, Acquisitions & Development at LUX MED
- **earlier** — Advisory Board Member and CFO at Picket Pharmaceuticals
- **2019** — Co-founded Auxilius Pharma with Uwe Tigör, MD; earned MHA from Columbia
- **2023** — Auxilius raised a $1M seed round and commenced its clinical program
- **2024** — FDA accepts 505(b)(2) pathway; Phase Ib bioequivalence study for AUX-001 prepared
- **2025** — Closed a $4M Series A in December to advance AUX-001 and Phase Ib

## Achievements

- Co-founded and leads Auxilius Pharma, focused on value-added cardiovascular medicines
- Advanced AUX-001 toward becoming the first new oral chronic stable angina therapy in the US since 2006
- Secured FDA acceptance of a 505(b)(2) regulatory pathway, bypassing Phase II
- Raised roughly $7.8M in total funding across seed and Series A rounds
- Earned an Executive MHA from Columbia University Mailman School of Public Health

## Latest updates

- **2025-12** — Auxilius Pharma announced a $4 million Series A financing to complete pharmaceutical optimization and a Phase Ib trial for AUX-001.

## Links

- Website: https://auxiliuspharma.com
- LinkedIn: http://www.linkedin.com/in/jedrzej-litwiniuk-mha-0102ab

---

Profile page: https://yespress.io/jedrzej-litwiniuk
Published by YesPress — https://yespress.io
Last updated: 2026-06-11